Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Diabetology International
Erschienen in: Diabetology International 3/2020

24.07.2020 | Guideline

Japanese Clinical Practice Guideline for Diabetes 2019

verfasst von: Eiichi Araki, Atsushi Goto, Tatsuya Kondo, Mitsuhiko Noda, Hiroshi Noto, Hideki Origasa, Haruhiko Osawa, Akihiko Taguchi, Yukio Tanizawa, Kazuyuki Tobe, Narihito Yoshioka

Erschienen in: Diabetology International | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline for Diabetes” which has been revised every three years since its first appearance in 2004 to promote evidence-based, rational, efficient and consistent clinical practice in diabetes. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Kosaka K, Akanuma Y, Goto Y, et al. Report of Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 1982;25:859–66 (in Japanese).
2.
3.
Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee of Japan Diabetes Society on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 1999;42:385–404 (in Japanese).
4.
Seino Y, Nanjo K, Tajima N. et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus: the Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Diabetol Int. 2010;1:2.
5.
American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S13–27.
6.
Kadowaki T, Haneda M, Tominaga M, et al. Report of the Japan Diabetes Society’s Committee on the diagnostic criteria for diabetes mellitus and glucose metabolism disorder—a new category of fasting plasma glucose values: “high-normal”. J Jpn Diabetes Soc. 2008;51:281–3 (in Japanese).
7.
Kawasaki E, Maruyama T, Imagawa A, et al. Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus. Diabetol Int. 2012;2013(4):221.
8.
Tanaka S, Ohmori M, Awata T, et al. Erratum to: Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus of the Japan Diabetes Society. Diabetol Int. 2012;2015(6):149.
9.
Imagawa A, Hanafusa T, Awata T, et al. Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus (2012). Diabetol Int. 2012;3:179–83.
1.
United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
2.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13.PubMedPubMedCentral
3.
Look ARG, Gregg EW, Jakicic JM, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4:913–21.
4.
Sone H, Tanaka S, Tanaka S, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011;96:3448–56.PubMed
5.
Ueki K, Sasako T, Okazaki Y, Group JDS, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951–64.PubMed
1.
Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50 [level 1]
2.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403 [level 1]
3.
The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54 [level 1]
4.
Terranova CO, Brakenridge CL, Lawler SP, et al. Effectiveness of lifestyle-based weight loss interventions for adults with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2015;17:371–8 [level 1]
5.
Chen L, Pei JH, Kuang J, et al. Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism. 2015;64:338–47 [level 1]
6.
Huang XL, Pan JH, Chen D, et al. Efficacy of lifestyle interventions in patients with type 2 diabetes: , systematic review and meta-analysis. Eur J Intern Med. 2016;27:37–47 [level 1]
7.
Zhang X, Devlin HM, Smith B, et al. Effect of lifestyle interventions on cardiovascular risk factors among adults without impaired glucose tolerance or diabetes: a systematic review and meta-analysis. PLoS One. 2017;12:e0176436 [level 1]
8.
Franz MJ, Boucher JL, Rutten-Ramos S, et al. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115:1447–63 [level 1]
9.
Fu S, Li L, Deng S, et al. Effectiveness of advanced carbohydrate counting in type 1 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;6:37067 [level 2]
10.
Møller G, Andersen HK, Snorgaard O. A systematic review and meta-analysis of nutrition therapy compared with dietary advice in patients with type 2 diabetes. Am J Clin Nutr. 2017;106:1394–400 [level 1]
11.
Huang MC, Hsu CC, Wang HS, et al. Prospective randomized controlled trial to evaluate effectiveness of registered dietitian-led diabetes management on glycemic and diet control in a primary care setting in Taiwan. Diabetes Care. 2010;33:233–9 [level 1]
12.
Emadian A, Andrews RC, England CY, et al. The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. Br J Nutr. 2015;114:1656–66.PubMedPubMedCentral
13.
Ahmadi-Abhari S, Robert N, et al. Dietary intake of carbohydrates and risk of type 2 diabetes: the European Prospective Investigation into Cancer-Norfolk study. Br J Nutr. 2014;111:342–52.PubMed
14.
Noto H, Goto A, Tsujimoto T, et al. Long-term low-carbohydrate diets and type 2 diabetes risk: a systematic review and meta-analysis of observational studies. J Gen Fam Med. 2016;17:60–70.
15.
Muraki I, Imamura F, Manson JE, et al. Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. BMJ. 2013;347:f5001.PubMedPubMedCentral
16.
Bazzano LA, Li TY, Joshipura KJ, et al. Intake of fruit, vegetables, and fruit juices and risk of diabetes in women. Diabetes Care. 2008;31:1311–7.PubMedPubMedCentral
17.
Halbesma N, Bakker SJ, Jansen DF, et al. High protein intake associates with cardiovascular events but not with loss of renal function. J Am Soc Nephrol. 2009;20:1797–804.PubMedPubMedCentral
18.
Pedersen AN, Kondrup J, Børsheim E. Health effects of protein intake in healthy adults: a systematic literature review. Food Nutr Res. 2013;57:21245.
19.
Guasch-Ferré M, Becerra-Tomás N, Ruiz-Canela M, et al. Total and subtypes of dietary fat intake and risk of type 2 diabetes mellitus in the Prevencio´ n con Dieta Mediterra´ nea (PREDIMED) study. Am J Clin Nutr. 2017;105:723–35.PubMed
20.
Tobias DK, Chen M, Hu FB, et al. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:968–79.PubMedPubMedCentral
21.
Wang L, Folsom AR, Eckfeldt JH, et al. ARIC Study Investigators. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr. 2003;78:91–8.
22.
Hodge AM, English DR, Giles GG, et al. Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: interpreting the role of linoleic acid. Am J Clin Nutr. 2007;86:189–97.PubMed
23.
Harding AH, Day NE, Wareham NJ, et al. Dietary fat and the risk of clinical type 2 diabetes: the European prospective investigation of Cancer-Norfolk. Am J Epidemiol. 2004;159:73–82.PubMed
1.
Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305:1790–9 [level 1+]
2.
Boulé NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286:1218–27 [level 2]
3.
Pai LW, Li TC, Hwu YJ, et al. The effectiveness of regular leisure-time physical activities on long-term glycemic control in people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;113:77–85 [level 2]
4.
Boniol M, Dragomir M, Autier P, et al. Physical activity and change in fasting glucose and HbA1c: a quantitative meta-analysis of randomized trials. Acta Diabetol. 2017;54:983–91 [level 1+]
5.
MacLeod SF, Terada T, Chahal BS, et al. Exercise lowers postprandial glucose but not fasting glucose in type 2 diabetes: a meta-analysis of studies using continuous glucose monitoring. Diabetes Metab Res Rev. 2013;29:593–603 [level 2]
6.
Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care. 2006;29:2518–27 [level 2]
7.
Qiu S, Cai X, Schumann U, et al. Impact of walking on glycemic control and other cardiovascular risk factors in type 2 diabetes: a meta-analysis. PLoS One. 2014;9:e109767 [level 1+]
8.
Schwingshackl L, Missbach B, Dias S, et al. Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2014;57:1789–97 [level 1+]
9.
Figueira FR, Umpierre D, Cureau FV, et al. Association between physical activity advice only or structured exercise training with blood pressure levels in patients with type 2 diabetes: a systematic review and meta-analysis. Sports Med. 2014;44:1557–72 [level 1+]
10.
Boulé NG, Kenny GP, Haddad E, et al. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus. Diabetologia. 2003;46:1071–81 (level 1+)
11.
Kelley GA, Kelley KS. Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials. Public Health. 2007;121:643–55 [level 1+]
12.
Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006:CD002968 [level 2]
13.
Hayashino Y, Jackson JL, Fukumori N, et al. Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2012;98:349–60 [level 1+]
14.
Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34:1228–37 [level 1+]
15.
Ostman C, Jewiss D, King N, et al. Clinical outcomes to exercise training in Type 1 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2018;139:380–91 [level 2]
16.
Yardley JE, Hay J, Abou-Setta AM, et al. A systematic review and meta-analysis of exercise interventions in adults with type 1 diabetes. Diabetes Res Clin Pract. 2014;106:393–400 [level 2]
17.
Tonoli C, Heyman E, Roelands B, et al. Effects of different types of acute and chronic (training) exercise on glycaemic control in type 1 diabetes mellitus: a meta-analysis. Sports Med. 2012;42:1059–80 [level 2]
18.
Kennedy A, Nirantharakumar K, Chimen M, et al. Does exercise improve glycaemic control in type 1 diabetes? A systematic review and meta-analysis. PLoS One. 2013;8:e58861 [level 2]
19.
Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39:2065–79.PubMedPubMedCentral
20.
Colberg SR, Sigal RJ, Fernhall B, American Diabetes Association, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care. 2010;33:e147–67.PubMedPubMedCentral
21.
American Diabetes Association. 4. Lifestyle Management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S38–50.
1.
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83–8.
2.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedPubMedCentral
3.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53.
4.
Bennett WL, Wilson LM, Bolen S, et al. Oral diabetes medications for adults with type 2 diabetes: an update. Agency for Healthcare Research and Quality (US), Rockville (MD); 2011.
5.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–65.
6.
Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168:2070–80.PubMedPubMedCentral
7.
Kaku K, Tajima N, Kawamori R, et al. Melbin Observational Research (MORE) study of metformin therapy in patients with type 2 diabetes mellitus. J Jpn Diabetes Soc. 2006;49:325–31 (in Japanese).
8.
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701.PubMedPubMedCentral
9.
Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820–5.PubMed
10.
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–9.PubMedPubMedCentral
11.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–35.PubMed
12.
Colhoun HM, Livingstone SJ, Looker HC, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia. 2012;55:2929–37.PubMedPubMedCentral
13.
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–73.PubMed
14.
Tajima N, Kadowaki T, Odawara M et al: Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011:32–44.
15.
Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab. 2014;16:418–25.PubMed
16.
Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733–45.PubMed
17.
Iwakura T, Fujimoto K, Tahara Y, et al. A case of severe hypoglycemia induced by sitagliptin added to ongoing glimepiride therapy in patients with type 2 diabetes. J Jpn Diabetes Soc. 2010;53:505–8 (in Japanese).
18.
Kadowaki T, Tajima N, Odawara M, et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int. 2013;7:160–72.
19.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.PubMed
20.
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.PubMed
21.
Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 dibetes. N Engl J Med. 2015;373:232–42.PubMed
22.
Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA Randomized Clinical Trial. JAMA. 2019;321:69–79.PubMed
23.
Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:341–7.PubMed
24.
Seino Y, Min KW, Niemoeller E. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14:910–7.PubMedPubMedCentral
25.
Storgaard H, Cold F, Gluud LL, et al. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:906–8.PubMed
26.
Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40:647–54.PubMed
27.
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.PubMed
28.
Steinberg WM, Buse JB, Ghorbani MLM, et al. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diabetes Care. 2017;40:966–72.PubMed
29.
Marso SP, Holst AG, Vilsboll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376:891–2.PubMed
30.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.PubMedPubMedCentral
31.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30.PubMed
32.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.PubMed
33.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.PubMed
34.
Li DD, Wang TS, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348–55.PubMed
35.
Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–69.PubMed
36.
Kaku K, Sumino S, Katou M, et al. Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:463–7.PubMedPubMedCentral
37.
Ono Y, Nakamura A, Cho KY, et al. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2014;15:311–24.PubMed
38.
Aoki C, Suzuki K, Kuroda H, et al. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Nagoya J Med Sci. 2017;79:9–16.PubMedPubMedCentral
39.
Kadowaki T, Inagaki N, Kondo K, et al. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19:874–82.PubMedPubMedCentral
40.
Kaku K, Inagaki N, Kobayashi N. Long-term effects of mitiglinide in Japanese diabetics inadequately controlled with DPP-4 inhibitor or biguanide monotherapy. Diabetes Ther. 2014;5:97–111.PubMedPubMedCentral
41.
Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001;18:828–34.PubMed
42.
Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119–24.PubMed
43.
Van Gaal L, Maislos M, Schernthaner G, et al. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab. 2001;3:326–31.PubMed
44.
Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22:1395–409.
45.
Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65–74.PubMed
46.
DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.PubMed
47.
Derosa G, Salvadeo SA, D’Angelo A, et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin. 2009;25:607–15.PubMed
48.
Scheen AJ, Tan MH, Betteridge DJ, et al. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabet Med. 2009;26:1033–9.PubMed
49.
Lukashevich V, Del Prato S, Araga M, et al. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16:403–9.PubMed
50.
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.PubMed
51.
Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267–82.PubMedPubMedCentral
1.
The Diabetes Control and Complications Trial (DCCT) Research Group: early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–86.
2.
Takahashi Y, Takayama S, Ito T, et al. Clinical features of eighty-six diabetic patients with post-treatment painful neuropathy. J Jpn Diabetes Soc. 1998;41:165–70 (in Japanese).
3.
United Kingdom Prospective Diabetes Study (UKPDS) Group: United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165–75.
4.
The Diabetes Control and Complications Trial (DCCT) Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86 [level 1]
5.
The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998;41:416–23 [level 1]
6.
Kahler P, Grevstad B, Almdal T, et al. Targeting intensive versus conventional glycemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analysis of randomized clinical trials. BMJ Open. 2014;4:e004806 [level 1+]
7.
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53 [level 1]
8.
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17 [level 2]
9.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53 [level 1]
10.
Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–9.PubMed
11.
Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–30.PubMed
12.
Liebl A, Prager R, Binz K, et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009;11:45–52.PubMed
13.
Feinglos MN, Thacker CR, Lobaugh B, et al. Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus. Diabetes Res Clin Pract. 1998;39:193–9.PubMed
14.
Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330–36.
15.
Ozbek M, Erdogan M, Karadeniz M, et al. Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment. Acta Diabetol. 2006;43:148–51.PubMed
16.
De Luis DA, Aller R, Cuellar L, et al. Effect of Repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:1844–55.PubMed
17.
Yamada S, Watanabe M, Funae O, et al. Effect of combination therapy of a rapid-acting insulin secretagogue (Glinide) with premixed insulin in type 2 diabetes mellitus. Intern Med. 2007;46:1893–7.PubMed
18.
Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:182–8.PubMed
19.
Relimpio F, Pumar A, Losada F, et al. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial. Diabet Med. 1998;15:997–1002.PubMed
20.
Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1999;130:389–96.PubMed
21.
Ponssen HH, Elte JW, Lehert P, et al. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther. 2000;22:709–18.PubMed
22.
Juntti-Berggren L, Pigon J, Hellström P, et al. Influence of acarbose on post-prandial insulin requirements in patients with type 1 diabetes. Diabetes Nutr Metab. 2000;13:7–12.PubMed
23.
Han A, Katoh S, Nemoto M, et al. Effect of combination therapy of premixtured 50 R and voglibose in patients with type 2 diabetes. J Jpn Diabetes Soc. 2004;47:137–40 (in Japanese).
24.
Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin-treated patients with typeII diabetes mellitus: Troglitazone and Exogenous Insulin Study Group. N Engl J Med. 1998;338:861–6.PubMed
25.
Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther. 2005;27:554–67.PubMed
26.
Bhat R, Bhansali A, Bhadada S, et al. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract. 2007;78:349–54.PubMed
27.
Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226–32.PubMed
28.
Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167–77.PubMed
29.
Terauchi Y, Tamura M, Senda M, et al. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). Diabetes Obes Metab. 2018;1–10:2018.
30.
Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–34.PubMed
31.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.PubMed
32.
The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–28.PubMedCentral
1.
He X, Li J, Wang B, et al. Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine. 2017;55:712–31 [level 1+]
2.
Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet. 2004;363(9421):1589–97 [level 2]
3.
Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med. 2015;163:848–60 [level 2]
4.
Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 1 diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2015;163:836–47 [level 2]
5.
Rickheim PL, Weaver TW, Flader JL, et al. Assessment of group versus individual diabetes education: a randomized study. Diabetes Care. 2002;25:269–74 [level 1]
6.
Trento M, Gamba S, Gentile L, et al. Rethink Organization to iMprove Education and Outcomes (ROMEO): a multicenter randomized trial of lifestyle intervention by group care to manage type 2 diabetes. Diabetes Care. 2010;33:745–47 [level 2]
7.
Duke S-AS, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2009;21(1):CD005268 [level 2]
8.
Odgers-Jewell K, Ball LE, Kelly JT, et al. Effectiveness of group-based self-management education for individuals with Type 2 diabetes: a systematic review with meta-analyses and meta-regression. Diabet Med. 2017;34:1027–39 [level 2]
9.
Diabetes Control Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86 [level 1]
10.
Miller KM, Beck RW, Bergenstal RM, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013;36:2009–14 [level 2]
11.
Ziegler R, Heidtmann B, Hilgard D, et al. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2011;12:11–7 (level 2)
12.
Murata GH, Shah JH, Hoffman RM, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care. 2003;26:1759–63 [level 2]
13.
Poolsup N, Suksomboon N, Kyaw AM. Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. Diabetol Metab Syndr. 2013;5:39.PubMedPubMedCentral
14.
Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317:379–87.PubMed
15.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371–8.PubMed
16.
Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254–63.PubMed
17.
Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.PubMed
18.
Fisher L, Hessler D, Polonsky W, et al. Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. J Diabetes Complicat. 2016;30:1123–8.
19.
Perrin NE, Davies MJ, Robertson N, et al. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2017;34:1508–20.PubMed
20.
Li C, Barker L, Ford ES, et al. Diabetes and anxiety in US adults: findings from the 2006 Behavioral Risk Factor Surveillance System. Diabet Med. 2008;25:878–81.PubMed
21.
Hessler DM, Fisher L, Polonsky WH, et al. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabet Med. 2017;34:1228–34.PubMedPubMedCentral
22.
Schmitz N, Gariépy G, Smith KJ, et al. Recurrent subthreshold depression in type 2 diabetes: an important risk factor for poor health outcomes. Diabetes Care. 2014;37:970–8.PubMed
23.
Chew BH, Vos RC, Metzendorf MI et al: Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;9:CD011469.
24.
Avery L, Flynn D, van Wersch A, et al. Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care. 2012;35:2681–9 [level 2]
25.
Cradock KA, ÓLaighin G, Finucane FM et al: Behaviour change techniques targeting both diet and physical activity in type 2 diabetes: a systematic review and meta-analysis. Int J Behav Nutr Phys Act. 2017;14(1):18 [level 1+]
26.
Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363:2611–20.PubMedPubMedCentral
27.
Huang Y, Wei X, Wu T, et al. Collaborative care for patients with depression and diabetes mellitus: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:260.PubMedPubMedCentral
1.
Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107:237–43 [level 2]
2.
Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989;107:244–9 [level 2]
3.
Younis N, Broadbent DM, Vora JP, et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361:195–200 [level 2]
4.
Misra A, Bachmann MO, Greenwood RH, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med. 2009;26:1040–7 [level 2]
5.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86 [level 1]
6.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53 [level 1]
7.
Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–244 [level 1]
8.
Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7 [level 1+]
9.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13 [level 1]
10.
UK Prospective Diabetes Study (UKPDS) Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Opthalmol. 2004;122:1631–40 [level 1]
11.
Wang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetes retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:263–74 [level 1+]
12.
Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–97 [level 1]
13.
The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978;85:82–106 [level 1]
14.
Evans JR, Michelessi M, Virgili G:. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014;11:CD011234 [level 1+]
15.
Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care. 2002;25:859–64.PubMed
16.
Cheung N, Wang JJ, Klein R, et al. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007;30:1742–6.PubMed
17.
Cheung N, Rogers S, Couper DJ, et al. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke. 2007;38:398–401.PubMed
18.
Gerstein HC, Ambrosius WT, Danis R, et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care. 2013;36:1266–71.PubMedPubMedCentral
19.
Kramer CK, Rodrigues TC, Canani LH, et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care. 2011;34:1238–44.PubMedPubMedCentral
20.
Kawasaki R, Tanaka S, Tanaka S, et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. Ophthalmology. 2013;120:574–82.
1.
Katayama S, Moriya T, Tanaka S, et al. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011;54:1025–31 [level 2]
2.
Moriya T, Tanaka S, Kawasaki R, et al. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study. Diabetes Care. 2013;36:2803–9 [level 2]
3.
Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMed
4.
Horio M, Imai E, Yasuda Y, et al. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61:197–203.PubMed
5.
Diabetes C, Complications Trial Research G, Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86 [level 1]
6.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53 [level 1]
7.
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17 [level 1]
8.
Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30 [level 1]
9.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39 [level 1]
10.
ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72 [level 1]
11.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–13 [level 1]
12.
Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–8 [level 1]
13.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60 [level 1]
14.
Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011;54:280–90 [level 3]
15.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54:810–9 [level 3]
16.
Shen X, Zhang Z, Zhang X, et al. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2016;15:179 [level 2]
17.
Haneda M, Kikkawa R, Sakai H, et al. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract. 2004;66:87–95 [level 1]
18.
Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–33 [level 1+]
19.
Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–56 [level 1+]
20.
Suckling RJ, He FJ, MacGregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010;(12):CD006763 [level 2]
21.
Hansen HP, Tauber-Lassen E, Jensen BR, et al. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62:220–8.PubMed
22.
Nezu U, Kamiyama H, Kondo Y et al: Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. BMJ Open. 2013;3
23.
Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.PubMed
24.
Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302–8.PubMedPubMedCentral
1.
Hotta N, Toyoda R, et al. Diabetic neuropathy. Kanehara, Tokyo; 1996. p. 145–54 (in Japanese).
2.
Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–62.PubMed
3.
Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341–50.PubMed
4.
Clair C, Cohen MJ, Eichler F, et al. The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med. 2015;30:1193–203.PubMedPubMedCentral
5.
Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care. 2017;40:1226–32.PubMedPubMedCentral
6.
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary, P et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86 [level 1]
7.
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17 [level 2]
8.
Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30 [level 1]
9.
Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37:589–96.PubMed
10.
Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448–54.PubMedPubMedCentral
11.
Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial. J Diabetes Investig. 2011;2:457–63.PubMedPubMedCentral
12.
Pritchett YL, McCarberg BH, Watkin JG, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med. 2007;8:397–409.PubMed
13.
Yasuda H, Hotta N, Nakao K, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan. J Diabetes Investig. 2011;2:132–9.PubMed
14.
Charles M, Soedamah-Muthu SS, Tesfaye S, et al. Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2010;33:2648–53.PubMedPubMedCentral
1.
2.
Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders: a clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45:S1–66.PubMed
3.
Krishinan S, Nash F, Baker N, et al. Reduction in diabetic amputations over 11 years in a defined U.K. population benefits of multidisciplinary team work and continuous prospective audit. Diabetes Care. 2008;31:99–101 [level 2]
4.
Malone JM, Snyder M, Anderson G, et al. Prevention of amputation by diabetic education. Am J Surg. 1989;158:520–4 [level 1]
5.
Bonner T, Foster M, Spears-Lanoix E. Type 2 diabetes related foot care knowledge and foot self-care practice interventions in the United States: a systematic review of the literature. Diabet Foot Ankle. 2016;7:29758 [level 1]
6.
Stratton IM, Adler A, Meil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. 2000;321:405–2 [level 2]
7.
Hasan R, Firwana B, Elraiyah T, et al. A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. J Vasc Surg. 2016;63:22S–28S [level 1]
8.
Netten JJV, Price PE, Lavery LA, et al. Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. Diabetes Metab Res Rev. 2016;32(Suppl 1):84–98 [level 1]
9.
Weck M, Slesaczeck T, Hartmut Paetzold H, et al. Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates. Cardiovasc Diabetol. 2013;12:45 [level 2]
10.
Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:2020–45.PubMed
11.
Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54:e132–73.PubMed
12.
Armstrong DG, Bharara M, White M, et al. The impact and outcomes of establishing an integrated interdisciplinary surgical team to care for the diabetic foot. Diabetes Metab Res Rev. 2012;28:514–8 [level 3]
13.
Paisey RB, Abbott A, Levenson R, et al. Diabetes-related major lower limb amputation incidence is strongly related to diabetic foot service provision and improves with enhancement of services: peer review of the South-West of England. Diabet Med. 2018;35:53–62 [level 3]
14.
Hogg FRA, Peach G, Price P, et al. Measures of health-related quality of life in diabetes-related foot disease: a systematic review. Diabetologia. 2012;55:552–65 [level 1]
15.
Siersma V, Thorsen H, Holstein PF, et al. Diabetic complications do not hamper improvement of health-related quality of life over the course of treatment of diabetic foot ulcers—the Eurodiale study. J Diabetes Complicat. 2017;31:1145–51 [level 2]
16.
Brownrigg JR, Davey J, Holt PJ, et al. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes. Diabetologia. 2012;55:2906–12.PubMed
17.
Ismail K, Winkley K, Stahl D, et al. A cohort study of people with diabetes and their first foot ulcer. Diabetes Care. 2007;30:1473–9.PubMed
18.
Natovich R, Kushnir T, Harman-Boehm I, et al. Cognitive dysfunction: part and parcel of the diabetic foot. Diabetes Care. 2016;39:1202–7.PubMed
1.
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.PubMed
2.
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.PubMed
3.
Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298–307.PubMedPubMedCentral
4.
Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951–64.PubMed
5.
Miller ME, Williamson JD, Gerstein HC, ACCORD Investigators, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care. 2014;37:634–43.PubMedPubMedCentral
6.
Odden MC, Paralta CA, Haan MN, et al. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med. 2012;172:1162–8.PubMedPubMedCentral
7.
Wing RR; Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75 [level 1]
8.
Metz JA, Stern JS, Kris-Etherton P, et al. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med. 2000;160:2150–8 [level 1]
9.
Esposito K, Maiorino MI, Ciotola M, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med. 2009;151:306–14 [level 1]
10.
Roussel R, Steg PG, Mohammedi K, et al. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: a perspective on glucose-lowering interventions. Diabetes Obes Metab. 2018;20:238–244 [level 1+]
11.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12 [level 2]
12.
Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9 [level 2]
13.
Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–15 [level 1+]
14.
de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72:2365–73 [level 1+]
15.
de Vries FM, Kolthof J, Postma MJ, et al. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS One. 2014;9:e111247 [level 1+]
16.
Simpson SH, Gamble JM, Mereu L, et al. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med. 2011;26:1336–1344 [level 1+]
1.
Takahashi K, Nishimura F, Kurihara M, et al. Subgingival microflora and antibody responses against periodontal bacteria of young Japanese patients with type 1 diabetes mellitus. J Int Acad Periodontol. 2001;3:104–11.PubMed
2.
Morita I, Inagaki K, Nakamura F, et al. Relationship between periodontal status and levels of glycated hemoglobin. J Dent Res. 2012;91:161–6.PubMed
3.
Katagiri S, Nitta H, Nagasawa T et al: Effect of glycemic control on periodontitis in type 2 diabetic patients with periodontal disease. J Diabetes Investig. 2013;4:320–25 [level 2]
4.
Demmer RT, Jacobs DR, Desvarieux M. Periodontal disease and incident type 2 diabetes: results from the First National Health and Nutrition Examination Survey and its epidemiologic follow-up study. Diabetes Care. 2008;31:1373–9.PubMedPubMedCentral
5.
Graziani F, Gennai S, Solini A, et al. A systematic review and meta-analysis of epidemiologic observational evidence on the effect of periodontitis on diabetes An update of the EFP-AAP review. J Clin Periodontol. 2018;45:167–87.PubMed
6.
Engebretson S, Kocher T. Evidence that periodontal treatment improves diabetes outcomes: a systematic review and meta-analysis. J Periodontol. 2013;84:S153–69 [level 1+]
7.
Simpson TC, Weldon JC, Worthington HV, et al. Treatment of periodontal disease for glycaemic control in people with diabetes mellitus. Cochrane Database Syst Rev. 2015;11:CD004714 [level 1+]
1.
Matsuzawa Y, Sakata T, Ikeda Y, et al. Guidelines for the management of obesity disease. 2006;2006:1–91 (in Japanese).
2.
Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity; New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92
3.
Hayashi T, Boyko EJ, McNeely MJ, et al. Minimum waist and visceral fat values for identifying Japanese Americans at risk for the metabolic syndrome. Diabetes Care. 2007;30:120–7.PubMed
4.
Kashihara H, Lee JS, Kawakubo K, Tamura M, Akabayashi A. Criteria of waist circumference according to computed tomography-measured visceral fat area and the clustering of cardiovascular risk factors. Circ J. 2009;73:1881–6.PubMed
5.
Hiuge-Shimizu A, Kishida K, Funahashi T, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med. 2012;44:82–92.PubMed
6.
Saito Y, Shirai A, Nakamura M, et al. Diagnostic criteria for obesity disease. 2011;2011:1–78 (in Japanese).
7.
Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34.PubMed
8.
The Japan Diabetes Society: Treatment Guide for Diabetes 2018–2019: Bunkodo; 2018 (in Japanese)
9.
Madigan CD, Aveyard P, Jolly K, et al. Regular self-weighing to promote weight maintenance after intentional weight loss: a quasi-randomized contorolled trail. J Public Health (Oxf). 2014;36:259–67.
10.
Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract. 2014;105:313–21.PubMed
11.
Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus roux-en-y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017;13:170–180 [level 2]
12.
Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24:437–55 [level 2]
13.
Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149:275–87 [level 2]
14.
Yan Y, Sha Y, Yao G, et al. Roux-en-Y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e3462 [level 1]
15.
Committee on Diagnostic Criteria for Metabolic Syndrome. Metabolic syndrome: its definition and diagnostic criteria. J Jpn Soc Intern. 2005;94:794–9 (in Japanese).
1.
Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.PubMed
2.
Ueki K, Sasako T, Okazaki Y, Kato M, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endcrinol. 2017;5:951–64 [level 1]
3.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713–20 [level 1]
4.
Baba S. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54:191–201 [level 1]
5.
Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542–9 [level 1]
6.
Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000;57:590–600 [level 1]
7.
Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–52 [level 2]
8.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860 [level 1]
9.
Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens. 2000;18:1671–5 [level 1]
10.
Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.” Lancet. 2002;359:1004–10 [level 1]
11.
Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22:1613–22 [level 1]
12.
Nakao K, Hirata M, Oba K, et al. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res. 2010;33:600–6 [level 2]
13.
Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091–96 [level 1]
14.
Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–94 [level 2]
15.
Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597–603 [level 1]
16.
Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401–9 [level 1]
17.
Yamashita K, Kondo T, Muramatsu T, et al. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. Am J Cardiol. 2013;112:1750–6 [level 1]
18.
Yui Y, Sumiyoshi T, Kodama K, et al. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res. 2004;27:449–56 [level 1]
1.
Wang Y, Lammi-Keefe CJ, Hou L, et al. Impact of low-density lipoprotein cholesterol on cardiovascular outcomes in people with type 2 diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2013;102:65–75.PubMedPubMedCentral
2.
Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ. 1998;316:823–8.PubMedPubMedCentral
3.
Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129:999–1008.PubMed
4.
Toth PP, Simko RJ, Palli SR, et al. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012;11:109–109.PubMedPubMedCentral
5.
Heilbronn LK, Noakes M, Clifton PM. Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes. Diabetes Care. 1999;22:889–95 [level 2]
6.
Huang XL, Pan JH, Chen D, et al. Efficacy of lifestyle interventions in patients with type 2 diabetes: a systematic review and meta-analysis. Eur J Intern Med. 2016;27:37–47 [level 1+]
7.
Esposito K, Maiorino MI, Bellastella G, et al. A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open. 2015;5(8):e008222 [level 1+]
8.
Hartweg J, Perera R, Montori V, et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;CD003205 [level 1+]
9.
Hayashino Y, Jackson JL, Fukumori N, et al. Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2012;98:349–60 [level 2]
10.
Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;CD002968 [level 1+]
11.
Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155–63 [level 1]
12.
Cholesterol Treatment Trialists C, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25 [level 1+]
13.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96 [level 1]
14.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9 [level 1]
15.
Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16 [level 1]
16.
Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–7 [level 2]
17.
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91 [level 2]
18.
Ueki K, Sasako T, Okazaki Y, et al.; J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951–64 [level 1]
19.
Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85 [level 2]
20.
Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376 [level 1+]
21.
Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–20 [level 3]
22.
Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220–6 [level 3]
23.
Taguchi I, Iimuro S, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD). Circulation. 2018;137:1997–2009 [level 1]
24.
Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61 [level 1]
25.
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74 [level 1]
26.
Burgess DC, Hunt D, Li L, et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J. 2010;31:92–9 [level 3]
27.
Allemann S, Diem P, Egger M, et al. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin. 2006;22:617–23 [level 1]
28.
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–10 [level 2]
29.
Leiter LA, Betteridge DJ, Farnier M, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab. 2011;13:615–28 [level 2]
30.
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92 [level 1]
31.
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97 [level 1]
32.
Giugliano RP, Cannon CP, Blazing MA, et al.; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with vs. without diabetes: results from IMPROVE-IT. Circulation. 2018;137:1571–82 [level 2]
33.
Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403–10 [level 1+]
34.
Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22 [level 1]
35.
Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941–50 [level 2]
36.
Schwartz GG, Steg PG, Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107 [level 1]
1.
Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001;94:435–44 [level 2]
2.
Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009;32:1046–8 [level 2]
3.
Alwan N, Tuffnell DJ, West J. Treatments for gestational diabetes. Cochrane Database Syst Rev. 2009;8:CD003395 [level 1]
4.
Nachum Z, Ben-Shlomo I, Weiner E, et al. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ. 1999;319:1223–7 [level 1]
5.
Griffin ME, Coffey M, Johnson H, et al. Universal vs. risk factor-based screening for gestational diabetes mellitus: detection rates, gestation at diagnosis and outcome. Diabet Med. 2000;17:26–32.
6.
Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care. 2001;24:1739–44.PubMed
7.
Liu P, Xu L, Wang Y, et al. Association between perinatal outcomes and maternal pre-pregnancy body mass index. Obes Rev. 2016;17:1091–102.PubMed
8.
American Diabetes Association. Management of diabetes in Pregnancy. Diabetes Care. 2019;42:S165–72.
9.
10.
Hiramatsu Y. Workshop “Gestational diabetes mellitus and self monitoring of blood glucose (SMBG)”. Diabetes Pregnancy. 2015;15:89–90 (in Japanese).
11.
Ludwig DS, Currie J. The association between pregnancy weight gain and birthweight: a within-family comparison. Lancet. 2010;376:984–90.PubMedPubMedCentral
12.
Brown J, Ceysens G, Boulvain M. Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes. Cochrane Database Syst Rev. 2017;6:CD012202.
13.
Langer O, Rodriguez DA, Xenakis EM, et al. Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol. 1994;170:1036–46 (discussion 1046–1047)
14.
Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373:1773–9.PubMed
15.
Hiramatsu Y, Haneda M, et al. The joint committee with the Japan Society of Diabetes and Pregnancy and the Japan Diabetes Society “An abnormal glucose metabolism during pregnancy and the standardization of its diagnostic criteria.”. J Jpn Diabetes Soc. 2015;58:801–3 (in Japanese).
16.
de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237–41.PubMed
17.
Manderson JG, Patterson CC, Hadden DR, et al. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol. 2003;189:507–12.PubMed
18.
1.
ISPAD Clinical Practice Consensus Guidelines for Pediatric and Adolescent Diabetes 2014. Nankodo, Tokyo; 2015.
2.
Ascerini C, Craig ME, de Beaufort C, et al. ISPAD clinical practice consensus guidelines 2014 compendium. Introduction. Pediatr Diabetes. 2014;15(Suppl 20):1–3.
3.
Craig ME, Jefferies C, Dabelea D, et al. ISPAD clinical practice consensus guidelines 2014 compendium. Definition, epidemiology, and classification of diabetes in children and adlescents. Pediatr Diabetes. 2014;15(Suppl 20):4–17.
4.
White NH, Cleary PA, Dahms W, et al. (Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group). Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139:804–12.
5.
Urakami T, Morimoto S, Nitadori Y, et al. Urine glucose screening program at schools in Japan to detect children with diabetes and its outcome: incidence and clinical characteristics of childhood type 2 diabetes in Japan. Pediatr Res. 2007;61:141–5.PubMed
6.
Zeitler P, Fu J, Tandon N, et al. ISPAD clinical practice consensus guidelines 2014 compendium. Type 2 diabetes in the child and adolescent. Pediatr Diabetes. 2014;15(Suppl 20):26–46
7.
Urakami T, Suzuki J, Mugishima H, et al. Screening and treatment of childhood type 1 and type 2 diabetes mellitus in Japan. Pediatr Endocrinol Rev. 2012;10(Supple 1):51–61.
8.
Laffel L, Chang N, Grey M, et al. Metformin monotherapy in youth recent-onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. Pediatr Diabetes. 2012;13:369–75.PubMed
9.
Jones KL, Arslanian S, Peterokova VA, et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25:89–94.PubMed
10.
Matsuura N, Takeuchi M, Amemiya S, et al. Trial of metformin clinical trial of metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan. J Jpn Diabet Soc. 2008;51(5):427–34.
11.
Rubio-Cabezas O, Hattersley AT, Njölstad PR, et al. ISPAD clinical practice consensus guidelines 2014 compendium. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2014;15(Suppl 20):47–64.
12.
Rafiq M, Flanagan SE, Patch AM, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008;31:204–9.PubMed
13.
Lange K, Swift P, Pankowska E, et al. ISPAD clinical practice consensus guidelines 2014 compendium. Diabetes education. Pediatr Diabetes. 2014;15(Suppl 20):77–85.PubMed
14.
Winkley K, Landau S, Eisler I, et al. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomized controlled trials. BMJ. 2006;333:65–8.PubMedPubMedCentral
15.
Delamater AM, de Wit M, McDarby V, et al. ISPAD clinical practice consensus guidelines 2014 compendium. Psychological issues. Pediatr Diabetes. 2014;15(Suppl 20):232–44.PubMed
16.
Rewers M, Pillay K, de Beaufort C, et al. ISPAD clinical practice consensus guidelines 2014 compendium. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(Suppl 20):102–14.
1.
Nyenwe EA, Kitabchi AE. Evidence-based management of hyperglycemic emergencies in diabetes mellitus. Diabetes Res Clin Pract. 2011;94:340–51.PubMed
2.
Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32:1335–43.PubMedPubMedCentral
3.
Wolfsdorf JI, Allgrove J, Craig ME, Edge J, Glaser N, Jain V, Lee WW, Mungai LN, Rosenbloom AL, Sperling MA, Hanas R; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2014;15(Suppl 20):154–79
4.
Jeffrey A, Kraut MD, Nicolaos E, et al. Lactic acidosis. N Engl J Med. 2014;371:2309–19.
5.
American Diabetes Association. Standards of medical care in diabetes–2018. Diabetes Care. 2018;41:S1–157.
6.
Seaquist ER, Anderson J, Childs B, et al. American Diabetes Association: Endocrine Society: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab. 2013;98:1845–59.PubMed
7.
Nirmal J, Gregory M, Caputo GM, et al. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341:1906–12.
8.
NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97
9.
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). J Intensive Care. 2018;6:7.
10.
Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015;13:53.PubMedPubMedCentral
11.
Vamos EP, Pape UJ, Curcin V, et al. Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. CMAJ. 2016;188:E342–51.PubMedPubMedCentral
12.
Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;CD000422
13.
Brink S, Joel D, Laffel L, et al. Sick day management in children and adolescents with diabetes. Pediatr Diabetes. 2014;15:193–202.PubMed
1.
Doi Y, Ninomiya T, Hata J, et al. Two risk score models for predicting incident type 2 diabetes in Japan. Diabet Med. 2012;29:107–14
2.
Nanri A, Nakagawa T, Kuwahara K, et al. Development of risk score for predicting 3-year incidence of type 2 diabetes: Japan Epidemiology Collaboration on Occupational Health study. PLoS One. 2015;10:e0142779.PubMedPubMedCentral
3.
Heianza Y, Arase Y, Hsieh SD, et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon Hospital Health Management Center Study 6 (TOPICS 6). Diabetologia. 2012;55:3213–23.PubMed
4.
Maskarinec G, Erber E, Grandinetti A, et al. Diabetes incidence based on linkages with health plans: the multiethnic cohort. Diabetes. 2009;58:1732–8.PubMedPubMedCentral
5.
Chiu M, Austin PC, Manuel DG, et al. Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes Care. 2011;34:1741–8.PubMedPubMedCentral
6.
Hsu WC, Araneta MR, Kanaya AM, et al. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care. 2015;38:150–8.PubMed
7.
Bjerregaard LG, Jensen BW, Angquist L, et al. Change in overweight from childhood to early adulthood and risk of type 2 diabetes. N Engl J Med. 2018;378:1302–12.PubMed
8.
Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67:152–62 [level 1]
9.
Kawahara T, Takahashi K, Inazu T, et al. Reduced progression to type 2 diabetes from impaired glucose tolerance after a 2-day in-hospital diabetes educational program: the Joetsu Diabetes Prevention Trial. Diabetes Care. 2008;31:1949–54 [level 1]
10.
Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med. 2011;171:1352–60 [level 1]
11.
Booth H, Khan O, Prevost T, et al. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol. 2014;2:963–8.PubMed
12.
Aune D, Norat T, Leitzmann M, et al. Physical activity and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis. Eur J Epidemiol. 2015;30:529–42.PubMed
13.
Smith AD, Crippa A, Woodcock J, et al. Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies. Diabetologia. 2016;59:2527–45.PubMedPubMedCentral
14.
Grontved A, Pan A, Mekary RA, et al. Muscle-strengthening and conditioning activities and risk of type 2 diabetes: a prospective study in two cohorts of US women. PLoS Med. 2014;11:e1001587.PubMedPubMedCentral
15.
Grontved A, Rimm EB, Willett WC, et al. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med. 2012;172:1306–12.PubMed
16.
Grontved A, Hu FB. Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA. 2011;305:2448–55.PubMedPubMedCentral
17.
Biswas A, Oh PI, Faulkner GE, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med. 2015;162:123–32.PubMed
18.
Greenwood DC, Threapleton DE, Evans CE, et al. Glycemic index, glycemic load, carbohydrates, and type 2 diabetes: systematic review and dose-response meta-analysis of prospective studies. Diabetes Care. 2013;36:4166–71.PubMedPubMedCentral
19.
Bhupathiraju SN, Tobias DK, Malik VS, et al. Glycemic index, glycemic load, and risk of type 2 diabetes: results from 3 large US cohorts and an updated meta-analysis. Am J Clin Nutr. 2014;100:218–32.PubMedPubMedCentral
20.
Schulze MB, Schulz M, Heidemann C, et al. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med. 2007;167:956–65.PubMed
21.
Yao B, Fang H, Xu W, et al. Dietary fiber intake and risk of type 2 diabetes: a dose-response analysis of prospective studies. Eur J Epidemiol. 2014;29:79–88.PubMed
22.
Hata A, Doi Y, Ninomiya T, et al. Magnesium intake decreases type 2 diabetes risk through the improvement of insulin resistance and inflammation: the Hisayama study. Diabet Med. 2013;30:1487–94
23.
Fang X, Han H, Li M, et al. Dose-response relationship between dietary magnesium intake and risk of type 2 diabetes mellitus: a systematic review and meta-regression analysis of prospective cohort studies. Nutrients. 2016;8(11):E739.
24.
Knott C, Bell S, Britton A. Alcohol consumption and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of more than 1.9 million individuals from 38 observational studies. Diabetes Care. 2015;38:1804–12.
25.
Imamura F, O’Connor L, Ye Z, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ. 2015;351:h3576.PubMedPubMedCentral
26.
van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA. 2005;294:97–104.PubMed
27.
Yang WS, Wang WY, Fan WY, et al. Tea consumption and risk of type 2 diabetes: a dose-response meta-analysis of cohort studies. Br J Nutr. 2014;111:1329–39.PubMed
28.
Pan A, Wang Y, Talaei M, et al. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:958–67.PubMedPubMedCentral
29.
Shan Z, Ma H, Xie M, et al. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2015;38:529–37.PubMed
30.
Cappuccio FP, D’Elia L, Strazzullo P, et al. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33:414–20.PubMed
31.
Guo VY, Cao B, Wong CKH, et al. The association between daytime napping and risk of diabetes: a systematic review and meta-analysis of observational studies. Sleep Med. 2017;37:105–12.PubMed
32.
Rotella F, Mannucci E. Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. J Clin Psychiatry. 2013;74:31–7.PubMed
33.
Kato M, Noda M, Inoue M, et al. Psychological factors, coffee and risk of diabetes mellitus among middle-aged Japanese: a population-based prospective study in the JPHC study cohort. Endocr J. 2009;56:459–68.PubMed
34.
Vancampfort D, Rosenbaum S, Ward PB, et al. Type 2 diabetes among people with posttraumatic stress disorder: systematic review and meta-analysis. Psychosom Med. 2016;78:465–73.PubMed
35.
Vetter C, Dashti HS, Lane JM, et al. Night shift work, genetic risk, and type 2 diabetes in the UK Biobank. Diabetes Care. 2018;41:762–9.PubMedPubMedCentral
36.
Vetter C, Devore EE, Ramin CA, et al. Mismatch of sleep and work timing and risk of type 2 diabetes. Diabetes Care. 2015;38:1707–13.PubMedPubMedCentral
37.
Xu T, Magnusson Hanson LL, Lange T, et al. Workplace bullying and violence as risk factors for type 2 diabetes: a multicohort study and meta-analysis. Diabetologia. 2018;61:75–83.PubMed
38.
Kivimaki M, Virtanen M, Kawachi I, et al. Long working hours, socioeconomic status, and the risk of incident type 2 diabetes: a meta-analysis of published and unpublished data from 222,120 individuals. Lancet Diabetes Endocrinol. 2015;3:27–34.PubMedPubMedCentral
39.
Ferrie JE, Virtanen M, Jokela M, et al. Job insecurity and risk of diabetes: a meta-analysis of individual participant data. CMAJ. 2016;188:E447–55.PubMedPubMedCentral
40.
Ludwig J, Sanbonmatsu L, Gennetian L, et al. Neighborhoods, obesity, and diabetes—a randomized social experiment. N Engl J Med. 2011;365:1509–19.PubMedPubMedCentral
41.
Christine PJ, Auchincloss AH, Bertoni AG, et al. Longitudinal associations between neighborhood physical and social environments and incident type 2 diabetes mellitus: the Multi-Ethnic Study of Atherosclerosis (MESA). JAMA Intern Med. 2015;175:1311–20.PubMedPubMedCentral
42.
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3:866–75 [level 1]
43.
Lindstrom J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013;56:284–93 [level 1]
44.
Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7:452–61 [level 1]
45.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMed
46.
Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.PubMed
47.
Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care. 2005;28:736–44.PubMed
48.
Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.PubMed
49.
DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15.PubMed
50.
Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.PubMed
51.
le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–409.PubMed
52.
Li Z, Li Y, Liu Y, et al. Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: a network meta-analysis. J Clin Hypertens. 2017;19:1348–56.
53.
Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–7.PubMed
54.
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.PubMed
55.
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.PubMed
1.
Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–87.PubMed
2.
Larsson SC, Orsini N, Brismar K, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49:2819–23.PubMed
3.
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207–21.PubMed
4.
Kasuga M, Ueki K, Tajima N, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetol Int. 2013;2:81–96.
5.
Goto A, Noto H, Noda M, et al. Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report. Diabetol Int. 2016;7:12–5.PubMedPubMedCentral
6.
Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871–7.PubMed
7.
Sasazuki S, Charvat H, Hara A, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104:1499–507.PubMedPubMedCentral
8.
Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.PubMedPubMedCentral
9.
Barone BB, Yeh HC, Snyder CF, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care. 2010;33:931–9.PubMedPubMedCentral
10.
van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer. 2007;120:1986–92.PubMed
11.
Lee W, Yoon YS, Han HS, et al. Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma. J Surg Oncol. 2016;113:203–8.PubMed
1.
Guidelines for Prevention and Treatment of Osteoporosis. Life Science publishing.
2.
Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495–505.PubMed
3.
Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int. 2007;18:427–44.PubMed
4.
Weber DR, Haynes K, Leonard MB, et al. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN). Diabetes Care. 2015;38:1913–20.PubMedPubMedCentral
5.
Hothersall EJ, Livingstone SJ, Looker HC, et al. Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland. J Bone Miner Res. 2014;29:1054–60.PubMed
6.
Melton LJ 3rd, Leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008;23:1334–42.PubMedPubMedCentral
7.
Ma L, Oei L, Jiang L, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27:319–32.PubMedPubMedCentral
8.
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–9.PubMedPubMedCentral
9.
Keegan TH, Schwartz AV, Bauer DC, et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care. 2004;27:1547–53.PubMed
1.
Saito T, Gotoh M, Satomi S, et al. Islet transplantation using donors after cardiac death: report of the Japan Islet Transplantation Registry. Transplantation. 2010;90:740–7.PubMed
2.
Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293:830–5.PubMed
1.
Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017
Metadaten
Titel
Japanese Clinical Practice Guideline for Diabetes 2019
verfasst von
Eiichi Araki
Atsushi Goto
Tatsuya Kondo
Mitsuhiko Noda
Hiroshi Noto
Hideki Origasa
Haruhiko Osawa
Akihiko Taguchi
Yukio Tanizawa
Kazuyuki Tobe
Narihito Yoshioka
Publikationsdatum
24.07.2020
Verlag
Springer Singapore
Erschienen in
Diabetology International / Ausgabe 3/2020
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-020-00439-5

Weitere Artikel der Ausgabe 3/2020

Diabetology International 3/2020 Zur Ausgabe

Mini-Review

Promising roles of sodium–glucose cotransporter 2 inhibitors in heart failure prevention and treatment

Short Communication

Plasma lipopolysaccharide binding protein level statistically mediates between body mass index and chronic microinflammation in Japanese patients with type 1 diabetes

Original Article

Work-related, personal, and diabetes-related factors relevant to dropout from outpatient diabetes treatment visits among Japanese male employees with diabetes

Commentary

Ethics and practical mitigations for ongoing clinical trials during the COVID-19 pandemic

Original Article

Pathophysiology of gestational diabetes mellitus in lean Japanese pregnant women in relation to insulin secretion or insulin resistance

Mini-Review

Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

04.06.2024 Interventionelle Verfahren in der Kardiologie Nachrichten

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise